🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations Dr. Tolaney!

Dr. Adrienne Waks presents exciting updates from the AVIATOR trial, led by BCRF investigator Dr. Ian Krop, at #SABCS23. SABCS

Terrific #SABCS23 dinner with the Dana-Farber’s Breast Oncology Center family!

Every voice matters on #RareDiseaseDay. Let's shine a light on male breast cancer, a rare and often overlooked condition.  Let's unite, advocate and support much needed research, like the #ETHANstudy, to better understand #MaleBreastCancer.

In pts w/ HR+ mBC (with HER2low, or HER2 ultralow dz) TDXd led to a significant ⬆️ in PFS c/w TPC Press release out from DESTINY-Breast06 Will be very interested to see the data; will have profound impact on tx sequencing + could put an end to HER2low as a biomarker

Absolutely could not agree more—these two are a rockstar pair and Sara Tolaney is the epitome of a fantastic mentor!

Thrilled to share our labs latest work, now online Cancer Cell where we used positive-selection CRISPR screening to discover that POU2F3 is regulated by the mSWI/SNF complex cell.com/cancer-cell/fu… 1/

En route to the DFCI Medical Oncology Retreat! Sara Tolaney Erica Mayer Ada Waks Toni Choueiri, MD Dana-Farber’s Breast Oncology Center

Our ⁦⁦Dana-Farber⁩ dear colleague and force of nature ⁦Ann Partridge MD, MPH⁩ with the ⁦ESMO - Eur. Oncology⁩ 2024 award. Ann has been a pioneer in the field of young adults with cancer, cancer survivorship and disparities. ⁦Dana-Farber’s Breast Oncology Center⁩ ⁦Dana-Farber News⁩

Our review on dual HER2 inhibition is out!! Thanks to NatureRevClinOncol for this opportunity and to all co-authors for a wonderful collaboration!! Paolo Tarantino Sara Tolaney @prat_aleix

There’s few open questions as critical in oncology as ADC sequencing We’re trying to answer it with #SATEEN The first prospective trial of sacituzimab govitecan (+ trastuzumab) after T-DXd for HER2+ MBC Currently enrolling at Dana-Farber’s Breast Oncology Center

New #OpenAccess article from Dana-Farber investigators | Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2-positive breast cancer in the SEER database, 2010–2019 acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… Ada Waks Paolo Tarantino OncoAlert #BCSM

Patients with HER2+ metastatic breast cancer face a high risk of death due to CNS involvement, and those with CNS-only disease had longer overall survival. ja.ma/42DHmF4 Rabih Bou-Nassif

New Trial Alert! Dean Shumway Mayo Clinic leads Alliance A012301 (LoTam) to compare the effect of low dose tamoxifen to usual hormonal therapy in treating post-menopausal women with hormone positive, HER2 negative early-stage #breastcancer: bit.ly/Alliance-A0123… #NCI #NCTN #BCsm

SERENA-6: ctDNA guided approach to switching from AI to camizestrant upon development of ESR1m in combo with cdk4/6i demonstrates improvement in PFS! PFS2 + OS immature Could be a paradigm shift + could introduce ctDNA monitoring into practice astrazeneca.com/media-centre/p…

Excited to share our multicenter retrospective cohort study of ADC sequencing is now published in NPJ Breast! rdcu.be/ehTr6 Thanks to our co-authors for this great team effort! Hope Rugo Reshma Mahtani Ruta Rao

Research led by Dana-Farber's Dr. Adrienne Waks shows combination therapy of avutometinib, abemaciclib and fulvestrant is active, safe in CDK4/6 inhibitor–resistant HR+/HER2– metastatic breast cancer, reports OncLive.com from #AACR25. ➡️ bit.ly/3YTUmni

very interesting data from RCT that exercise reduces recurrence and improves OS in early colon cancer. We've waited a long time for data such as this nejm.org/doi/full/10.10…

Tremendous discussion of the SERENA-6 trial by Angie DeMichele, MD, MSCE, FASCO. Outstanding results, though not ready for clinical practice (yet). Important to take into account financial, psychological & systemic costs of the strategy. Make sure to review this presentation if you missed it.

TBCRC 040 (PREDICT-DNA trial): Dr. Natasha Hunter presents - -HER2+ or TN pts with MRD assay after NAT and pre surgery -in TNBC, ctDNA MRD status distinguished between those with RD who had excellent vs poor prognosis Heather Parsons Translational Breast Cancer Research Consortium Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) Ben Ho Park